ANI Pharmaceuticals shares surge 11.58% intraday after raising 2026 revenue guidance to $10.55-$11.15B and reporting 76% growth in Cortrophin Gel net income in 2025.

ANI Pharmaceuticals surged 11.58% intraday, driven by a 2026 revenue guidance of $10.55–11.15 billion exceeding expectations, a 76% year-on-year increase in Cortrophin Gel net revenue in 2025, and the rare disease business projected to account for 60% of 2026 revenue, with plans to expand the team for acute gouty arthritis.